Patents by Inventor Aaron Ken Sato

Aaron Ken Sato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tissue-specific Wnt signal enhancing molecules and uses thereof
    Patent number: 11958891
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 16, 2024
    Assignee: Surrozen Operating, Inc.
    Inventors: Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
  • WNT surrogate molecules and uses thereof
    Patent number: 11773171
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 3, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20230279101
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 7, 2023
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • Anti-LRP5/6 antibodies and methods of use
    Patent number: 11746150
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 5, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Parthasarathy Sampathkumar
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 11512128
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 29, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
    Publication number: 20210087280
    Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 25, 2021
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Chenggang LU, Parthasarathy SAMPATHKUMAR, Claudia Yvonne JANDA
  • ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE
    Publication number: 20210079089
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 18, 2021
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Parthasarathy SAMPATHKUMAR
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20210061903
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 4, 2021
    Inventors: AUSTIN L. GURNEY, Aaron Ken Sato, Christopher John Bond
  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20200308287
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: October 1, 2020
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 10730940
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 4, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
    Publication number: 20200048324
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 13, 2020
    Inventors: Zhengjian ZHANG, Jennifer Jean BRADY, Aaron Ken SATO, Wen-Chen YEH, Yang LI, Teppei YAMAGUCHI
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20190062424
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: August 29, 2018
    Publication date: February 28, 2019
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20180305449
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 25, 2018
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • Modified immunoglobulin molecules that specifically bind human VEGF and DLL4
    Patent number: 9879084
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 30, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20170234854
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, FUMIKO TAKADA AXELROD, TIMOTHY CHARLES HOEY, SANJEEV H. SATYAL, SATYAJIT SUJIT KUMAR MITRA
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20170198031
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles HOEY, Edward Thein Htun van der HORST, Aaron Ken SATO, Yuan Ching LIU, Maureen Fitch BRUHNS, John A. LEWICKI
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20170183406
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: January 9, 2017
    Publication date: June 29, 2017
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Christopher John Bond
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 9617340
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 11, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
  • Polynucleotides encoding VEGF/DLL4 binding agents
    Patent number: 9574009
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: February 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Antibodies against human FZD5 and FZD8
    Patent number: 9573998
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 21, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra